-+ 0.00%
-+ 0.00%
-+ 0.00%

Hansa Biopharma's Idefirix Used in First Living Donor Kidney Transplant in Australia

MT Newswires·08/18/2026 02:16:46
Listen to the news
02:16 AM EDT, 08/18/2026 (MT Newswires) -- Hansa Biopharma (HNSA.ST) said Tuesday the first living donor kidney transplant following treatment with its antibody-cleaving enzyme Idefirix was performed in Australia. Australia's Therapeutic Goods Administration approved Idefirix as a desensitization treatment for highly sensitized adult kidney transplant candidates who have a positive cross-match against a living or deceased donor. The biopharmaceutical company plans to track patient outcomes via an established Australian registry, with real-world clinical data expected to support future scientific publications.